{"id":2602,"date":"2016-04-01T17:58:00","date_gmt":"2016-04-01T17:58:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2602"},"modified":"2025-01-15T20:29:07","modified_gmt":"2025-01-15T20:29:07","slug":"mitigating-the-burden-of-hepatitis-c-virus-among-people-who-inject-drugs-in-belgium-2","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/mitigating-the-burden-of-hepatitis-c-virus-among-people-who-inject-drugs-in-belgium-2\/","title":{"rendered":"Att\u00e9nuer le fardeau du virus de l&#039;h\u00e9patite C chez les consommateurs de drogues injectables en Belgique"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Contexte et objectifs<\/h3>\n\n\n\n<p>En 2010, il y avait environ 10 100 PID en Belgique et 43% (34%-57%) \u00e9taient infect\u00e9s par le VHC. La compr\u00e9hension de la dynamique de transmission du VHC dans les populations \u00e0 haut risque et l&#039;\u00e9valuation de l&#039;impact potentiel de strat\u00e9gies de traitement am\u00e9lior\u00e9es contre le VHC n\u00e9cessitent des donn\u00e9es \u00e9pid\u00e9miologiques solides et une mod\u00e9lisation math\u00e9matique.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9thodes<\/h3>\n\n\n\n<p>La transmission CV a \u00e9t\u00e9 mod\u00e9lis\u00e9e \u00e0 l&#039;aide de cohortes pour suivre l&#039;incidence et la pr\u00e9valence du VHC parmi les PID actifs dans la population PIDI g\u00e9n\u00e9rale, TSO et NSP. Les hypoth\u00e8ses du mod\u00e8le ont \u00e9t\u00e9 tir\u00e9es de la litt\u00e9rature publi\u00e9e et d&#039;un consensus d&#039;experts. L&#039;impact relatif de l&#039;augmentation du nombre de PID trait\u00e9s avec de nouveaux AAD oraux a \u00e9t\u00e9 pris en compte.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">R\u00e9sultats<\/h3>\n\n\n\n<p>Si le paradigme de transmission actuel se poursuit, il y aura 2645 PID infect\u00e9s par le VHC en 2030. Le traitement annuel de 30 (1% de la population de 2015) ou 120 (4% de la population de 2015) PID infect\u00e9s par le VHC avec des AAD oraux entra\u00eenera des r\u00e9ductions de 5% et 25%, respectivement, chez les PDI infect\u00e9s par le VHC d&#039;ici 2030. Le traitement de 370 PID par an (12,51 TTP1T de la population de 2015) entra\u00eenera une r\u00e9duction&gt; 901 TTP1T d&#039;ici 2030.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conclusion<\/h3>\n\n\n\n<p>Le traitement d&#039;un petit nombre de PID peut entra\u00eener une r\u00e9duction substantielle de la pr\u00e9valence du VHC dans cette population; cependant, des niveaux \u00e9lev\u00e9s de traitement sont n\u00e9cessaires pour r\u00e9duire le pool viral et donc le risque d&#039;infections secondaires. Cette analyse appuie la mise en \u0153uvre d&#039;une strat\u00e9gie de d\u00e9pistage et de traitement chez les PDI lorsqu&#039;elle est combin\u00e9e \u00e0 une expansion des programmes de r\u00e9duction des m\u00e9faits.<\/p>\n\n\n\n<p><strong>Des pays:<\/strong> Belgique<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27382943\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background and aims In 2010, there were an estimated 10 100 PWID in Belgium and 43% (34%-57%) were HCV infected. Understanding HCV transmission dynamics in high-risk populations and assessing the potential impact of improved HCV treatment strategies requires robust epidemiological data and mathematical modeling. Methods CV transmission was modeled using cohorts to track HCV [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3493,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10,16],"publication-author":[488,1124,1125,1122,1123,494,1099],"class_list":["post-2602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","tag-pwid","publication-author-blach-s","publication-author-bourgeois-s","publication-author-brixko-c","publication-author-mathei-c","publication-author-mulkay-jp","publication-author-razavi-h","publication-author-robaeys-g"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=2602"}],"version-history":[{"count":7,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2602\/revisions"}],"predecessor-version":[{"id":7581,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/2602\/revisions\/7581"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3493"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=2602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=2602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=2602"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=2602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}